NCT02779686|Terminated
Study Stopped
Investigator left institution
PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration
PIIR
Loading search results
Investigator left institution
PIIR
Sponsor study identifier
observational
32
1 country
3
Study Start
January 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2012
Actual (reported)Study Completion
December 2012
Actual (reported)This study is being conducted to compare two different genetic tests developed to determine an individuals risk of developing serious vision threatening complications from age-related macular degeneration (ARMD).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2012
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2012
Date type not reportedThis date has not been verified as actual or estimated.
December 2012
Actual (reported)December 2012
Actual (reported)May 13, 2016
Actual (reported)May 20, 2016
Actual (reported)Risk score from RetnaGene
Risk score assigned after genetic analysis of a buccal swab by the RetnaGene (Sequenom) genetic test.
Day 1
Risk score from Macula Risk
Risk score assigned after genetic analysis of a buccal swab by the Macula Risk genetic test.
Day 1
Patient free of ARMD on clinical examination
Patients with evidence of ARMD on clinical examination
Caucasian patients over the age of 60
Rush University Medical Center
Chicago, Illinois, 60612, United States
Pepose Vision Institute
Chesterfield, Missouri, 63017, United States
University of Missouri-Columbia
Columbia, Missouri, 65212, United States
Seddon JM, Reynolds R, Maller J, Fagerness JA, Daly MJ, Rosner B. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci. 2009 May;50(5):2044-53. doi: 10.1167/iovs.08-3064. Epub 2008 Dec 30.
Hageman GS, Gehrs K, Lejnine S, Bansal AT, Deangelis MM, Guymer RH, Baird PN, Allikmets R, Deciu C, Oeth P, Perlee LT. Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration. Hum Genomics. 2011 Jul;5(5):420-40. doi: 10.1186/1479-7364-5-5-420.
Nancy Holekamp, MD
Pepose Vision Institute
Mathew MacCumber, MD, PhD
Rush University Medical Center
Arghavan Almony, MD
University of Missouri-Columbia
32 participants (actual enrollment reported by the registry).
First Submitted
May 13, 2016
First Posted
May 20, 2016
Study Start
January 2012
Date type not reportedThis date has not been verified as actual or estimated.
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
Contact the study team to confirm eligibility.
Zanke B, Hawken S, Carter R, Chow D. A genetic approach to stratification of risk for age-related macular degeneration. Can J Ophthalmol. 2010 Feb;45(1):22-7. doi: 10.3129/i09-209.
Primary Completion
December 2012
Actual (reported)Study Completion
December 2012
Actual (reported)Last Updated
October 4, 2016
Record last verified: 2016-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: